MA43869A - Anticorps anti-myl9 - Google Patents

Anticorps anti-myl9

Info

Publication number: MA43869A
Authority: MA; Morocco
Prior art keywords: myl9; antibodies; myl9 antibodies
Prior art date: 2016-01-12

Application number

MA043869A

Other languages

English (en)

Inventor

Ryu Gejima

Koji Hayashizaki

Toshifumi Hirayama

Toshio Imai

Jungo Kakuta

Motoko Kimura

Kenzo Muramoto

Toshinori Nakayama

Yoshimasa Sakamoto

Daisuke Tokita

Original Assignee

Eisai R&D Man Co Ltd

Univ Chiba Nat Univ Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-12

Filing date

2017-01-11

Publication date

2018-11-21

2017-01-11 Application filed by Eisai R&D Man Co Ltd, Univ Chiba Nat Univ Corp filed Critical Eisai R&D Man Co Ltd

2018-11-21 Publication of MA43869A publication Critical patent/MA43869A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Endocrinology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA043869A 2016-01-12 2017-01-11 Anticorps anti-myl9 MA43869A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2016003429		2016-01-12

Publications (1)

Publication Number	Publication Date
MA43869A true MA43869A (fr)	2018-11-21

Family

ID=59311587

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA043869A MA43869A (fr)	2016-01-12	2017-01-11	Anticorps anti-myl9

Country Status (14)

Country	Link
US (1)	US10513561B2 (fr)
EP (1)	EP3404040B1 (fr)
JP (1)	JP6872756B2 (fr)
KR (1)	KR20180098570A (fr)
CN (1)	CN108431037B (fr)
AU (1)	AU2017207082B2 (fr)
BR (1)	BR112018013807A2 (fr)
CA (1)	CA3008786A1 (fr)
ES (1)	ES2913162T3 (fr)
IL (1)	IL260083B2 (fr)
MA (1)	MA43869A (fr)
MX (1)	MX2018008358A (fr)
RU (1)	RU2741802C2 (fr)
WO (1)	WO2017122666A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021007108A1 (fr) *	2019-07-05	2021-01-14	Icahn School Of Medicine At Mount Sinai	Méthode de prévention contre la perte de cheveux
WO2024080377A1 (fr) *	2022-10-14	2024-04-18	国立大学法人千葉大学	Procédé de détection de l'hypertension pulmonaire et médicament pour la prévention ou le traitement de l'hypertension pulmonaire
CN118440198B (zh) *	2024-04-03	2024-11-15	武汉爱博泰克生物科技有限公司	抗人cd69蛋白的兔单克隆抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2305811A1 (fr) *	2005-07-27	2011-04-06	Oncotherapy Science, Inc.	Procédé de diagnostic du cancer pulmonaire à petites cellules
EP1912633A4 (fr)	2005-08-09	2009-10-21	Univ Virginia	Methodes et compositions destinees a inhiber la permeabilite vasculaire
JP4777785B2 (ja) *	2006-01-31	2011-09-21	独立行政法人科学技術振興機構	ケモカインレセプターｃｃｒ５のｎ末端領域に対する抗体酵素
US8415372B2 (en)	2007-02-27	2013-04-09	Asahi Kasei Pharma Corporation	Sulfonamide compound
NZ595825A (en) *	2009-04-20	2012-10-26	Kyowa Hakko Kirin Co Ltd	Antibody containing igg2 having amino acid mutation introduced therein
US9316646B2 (en) *	2009-04-23	2016-04-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-human ROR1 antibodies
ES2661601T3 (es) *	2009-08-07	2018-04-02	Kyowa Hakko Kirin Co., Ltd.	Anticuerpo humanizado antioligómero de amiloide-beta
CA2876517C (fr) *	2012-07-19	2019-01-08	Matthew Stuible	Anticorps anti-siglec-15
CA2890658A1 (fr) *	2012-11-09	2014-05-15	The Johns Hopkins University	Analyse genetique permettant de determiner un pronostic chez des patients atteints de la maladie de vaquez
WO2014192915A1 (fr)	2013-05-30	2014-12-04	国立大学法人千葉大学	Composition de traitement d'une maladie inflammatoire comprenant un anticorps anti-polypeptide régulateur de chaîne légère de myosine
ES2898650T3 (es)	2013-06-27	2022-03-08	Univ Monash	Proteínas de unión a IL-21 y usos de las mismas
ES2818800T3 (es) *	2014-06-11	2021-04-14	Idac Theranostics Inc	Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario

2017
- 2017-01-11 CA CA3008786A patent/CA3008786A1/fr active Pending
- 2017-01-11 IL IL260083A patent/IL260083B2/en unknown
- 2017-01-11 RU RU2018124601A patent/RU2741802C2/ru active
- 2017-01-11 BR BR112018013807-0A patent/BR112018013807A2/pt not_active Application Discontinuation
- 2017-01-11 WO PCT/JP2017/000605 patent/WO2017122666A1/fr active Application Filing
- 2017-01-11 ES ES17738420T patent/ES2913162T3/es active Active
- 2017-01-11 EP EP17738420.3A patent/EP3404040B1/fr active Active
- 2017-01-11 US US16/063,515 patent/US10513561B2/en active Active
- 2017-01-11 MX MX2018008358A patent/MX2018008358A/es unknown
- 2017-01-11 CN CN201780005696.9A patent/CN108431037B/zh active Active
- 2017-01-11 JP JP2017561129A patent/JP6872756B2/ja active Active
- 2017-01-11 MA MA043869A patent/MA43869A/fr unknown
- 2017-01-11 KR KR1020187019061A patent/KR20180098570A/ko not_active Application Discontinuation
- 2017-01-11 AU AU2017207082A patent/AU2017207082B2/en active Active

Also Published As

Publication number	Publication date
JP6872756B2 (ja)	2021-05-19
JPWO2017122666A1 (ja)	2018-11-01
AU2017207082A1 (en)	2018-07-05
WO2017122666A1 (fr)	2017-07-20
RU2018124601A (ru)	2020-02-14
RU2018124601A3 (fr)	2020-04-30
US10513561B2 (en)	2019-12-24
EP3404040A4 (fr)	2019-08-07
CN108431037A (zh)	2018-08-21
ES2913162T3 (es)	2022-05-31
MX2018008358A (es)	2018-09-21
US20190002588A1 (en)	2019-01-03
KR20180098570A (ko)	2018-09-04
EP3404040B1 (fr)	2022-03-02
CN108431037B (zh)	2021-12-17
AU2017207082B2 (en)	2023-07-13
RU2741802C2 (ru)	2021-01-28
BR112018013807A2 (pt)	2018-12-11
CA3008786A1 (fr)	2017-07-20
IL260083A (en)	2018-07-31
IL260083B2 (en)	2023-09-01
EP3404040A1 (fr)	2018-11-21
IL260083B1 (en)	2023-05-01

Publication	Publication Date	Title
FR21C1030I2 (fr)	2022-04-08	Conjugué anticorps anti-her2-médicament
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
DK3625259T3 (da)	2024-07-08	Anti-sirpalpha-antistoffer
EP3334757A4 (fr)	2019-04-03	Anticorps anti-tigit
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
MA45004A (fr)	2019-03-27	Anticorps spécifiques anti-wt1-hla
MA46057A (fr)	2019-07-03	Anticorps anti-ctla4
MA46041A (fr)	2021-03-24	Anticorps anti-tim -3
MA47472A (fr)	2019-12-18	Anticorps
EP3334824A4 (fr)	2019-01-23	Anticorps anti-pd-1
EP3661558A4 (fr)	2021-08-11	Anticorps anti-il1rap
MA53297A (fr)	2022-05-04	Anticorps anti-icos
EP3356420C0 (fr)	2023-11-01	Anticorps multispécifiques
MA50352A (fr)	2020-08-19	Anticorps multispécifiques
DK3344654T3 (da)	2021-01-18	Anti-lag-3-antistoffer
MA46272A (fr)	2019-07-31	Anticorps anti-cd27
EP3383915A4 (fr)	2019-07-24	Anticorps anti-pd-1
EP3691447A4 (fr)	2021-08-11	Anticorps anti-transthyrétine
DK3606961T3 (da)	2022-07-04	Garp-tgf-beta-antistoffer
MA44236A (fr)	2018-12-26	Anticorps anti-tgfbêta 2
DK3250593T3 (da)	2022-08-22	Anti-transthyretin-antistoffer
MA42843A (fr)	2018-07-25	Anticorps anti-cd115